Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061

Eric Van Cutsem*, Mayur Amonkar, Charles S. Fuchs, Maria Alsina, Mustafa Özgüroğlu, Yung Jue Bang, Hyun Cheol Chung, Kei Muro, Eray Goekkurt, Al B. Benson, Weijing Sun, Zev A. Wainberg, Josephine M. Norquist, Xinqun Chen, Chie Schin Shih, Kohei Shitara

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Background: In the primary analysis population (i.e., PD-L1 combined positive score [CPS] ≥ 1) of the phase 3 KEYNOTE-061 study (NCT02370498), pembrolizumab did not significantly prolong overall survival or progression-free survival. Pembrolizumab had a favorable safety profile in the all-patient population. We present results of prespecified health-related quality of life (HRQoL) analyses. Methods: HRQoL was measured using the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30), EORTC QLQ gastric cancer questionnaire (QLQ-STO22), and EuroQol 5-dimension, 3-level questionnaire (EQ-5D-3L). Data were analyzed from patients who received ≥ 1 dose of study treatment and who completed ≥ 1 HRQoL assessment. Key analyses included baseline to week 12 least-squares mean (LSM) change in global health status (GHS)/QoL, functional/symptom subscales, and time to deterioration (TTD; ≥ 10-point decrease from baseline) for specific subscales. Results: The HRQoL population included 371 patients (pembrolizumab, n = 188; paclitaxel, n = 183). Compliance and completion rates for all 3 questionnaires were similar in both groups at baseline and week 12. There was no difference in LSM change between groups (– 3.54; 95% CI – 8.92 to 1.84) in GHS/QoL at week 12. LSM change from baseline to week 12 for most QLQ-C30, QLQ-STO22, and EQ-5D-3L subscales indicated some worsening of QoL in both groups. TTD for GHS/QoL, nausea/vomiting, and appetite loss subscales in QLQ-C30 and the pain subscales in QLQ-STO22 were similar between treatment groups. Conclusions: In this population with advanced gastric and GEJ cancer receiving second-line treatment, HRQoL was similar in patients receiving pembrolizumab and those receiving paclitaxel. Clinical trial registry and number:, NCT02370498.

Original languageEnglish (US)
Pages (from-to)1330-1340
Number of pages11
JournalGastric Cancer
Issue number6
StatePublished - Nov 2021


  • Chemotherapy
  • Gastric cancer
  • HRQoL
  • Pembrolizumab

ASJC Scopus subject areas

  • Gastroenterology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061'. Together they form a unique fingerprint.

Cite this